{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105039","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.522589+00:00","generated_at":"2026-05-17T17:39:24.910737+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Treace Medical Q2 revenue $47.4M (+7% YoY); net loss narrows to $17.4M; FY guidance reaffirmed","bullets":["Revenue $47.4M in Q2 2025, up 7% from $44.5M in Q2 2024.","Net loss $(17.4)M ($(0.28)/share) vs $(21.2)M ($(0.34)/share) a year ago; 18% improvement.","Adjusted EBITDA loss improved 58% to $(3.6)M from $(8.7)M in Q2 2024.","Total liquidity $90.7M as of June 30, 2025 ($69.3M cash plus $21.4M revolver).","Full market release of Nanoplasty, Percuplasty 3D MIS Osteotomy, and SpeedMTP Fusion Systems."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105039","json":"https://secwatch.observer/filing/0000950170-25-105039.json","markdown":"https://secwatch.observer/filing/0000950170-25-105039.md","text":"https://secwatch.observer/filing/0000950170-25-105039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025105039/0000950170-25-105039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025105039/tmci-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:39:24.910737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}